. Author manuscript; available in PMC: 2022 May 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2021 May 1;87(1):671–679. doi: 10.1097/QAI.0000000000002639

Table 3.

Reasons for early study termination.

	N = 362
Participant relocated	123 (34.0%)
Unable to contact	80 (22.1%)
Unable to adhere to visit schedule	68 (18.8%)
Participant refused	60 (16.6%)
Participant incarcerated	8 (2.2%)
Investigator decision^*	6 (1.7%)
Inappropriate enrollment	4 (1.1%)
Death	4 (1.1%)
Duplicate screening/enrollment	2 (0.6%)
Other	7 (1.9%)

1 mental health concern, 1 dual enrollment, 1 unreliable participant, 1 misconduct, 2 travel/commute.

Early termination occurred when a participant was unable to complete final scheduled study visit, which is Week 104 for those who did not acquire HIV and Week 24 for those who acquired HIV.